Supplementary material to article by M. Inzinger et al. "Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria"

Table SV. Mean PASI reduction scores^{*a*} achieved with anti-tumour necrosis factor- α agents and statistical comparison (intention-to-treat analysis)

Time-point (months)	Mean-PASI-reduction score (treatment cycles, <i>n</i>)			<i>p</i> -value ^b		
	Adalimumab	Etanercept	Infliximab	Adalimumab vs. Etanercept ^b	Adalimumab vs. Infliximab ^b	Infliximab vs. Etanercept ^b
4	3.1 (406)	3.4 (449)	3.0 (53)	7.6e-06*	0.66	0.02*
6	2.8 (363)	3.2 (412)	2.8 (45)	4.3e-05*	0.83	0.03*
12	2.4 (259)	2.9 (330)	3.1 (36)	1.9e-06*	0.002*	0.26
24	2.2 (152)	2.8 (246)	3.0 (17)	1.3e-07*	0.003*	0.34
36	2.3 (82)	2.8 (184)	2.3 (11)	1.1e-04*	0.95	0.15
48	2.3 (25)	2.7 (136)	2.5 (6)	3.6e-02*	0.67	0.46

^aAs described in Materials and Methods.^bGeneralized estimating equation was used to compare effectiveness data. All statistical tests were 2-sided at the 0.05 significance level.

PASI: Psoriasis Area and Severity Index.